CKD 344
Alternative Names: CKD-344Latest Information Update: 28 May 2024
At a glance
- Originator Chong Kun Dang
- Class Anticoagulants
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Blood coagulation disorders
Most Recent Events
- 28 May 2024 No recent reports of development identified for phase-I development in Blood-coagulation-disorders(In volunteers) in South Korea
- 27 Apr 2021 Phase-I clinical trials in Blood coagulation disorders (In volunteers) in South Korea (unspecified route) (NCT04867200)
- 13 Nov 2020 Chong Kun Dang Pharmaceutical initiates a phase I clinical trials in Blood coagulation disorders (In volunteers) in South Korea (unspecified route) (NCT04673695)